These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 37699422)
1. End-of-life care in cystic fibrosis in the era of new therapies. Dellon EP; Goggin J Lancet Respir Med; 2023 Oct; 11(10):861-863. PubMed ID: 37699422 [No Abstract] [Full Text] [Related]
3. New therapies in cystic fibrosis. Ratjen F; Grasemann H Curr Pharm Des; 2012; 18(5):614-27. PubMed ID: 22229570 [TBL] [Abstract][Full Text] [Related]
4. Promising new era dawns for cystic fibrosis treatment. Corbyn Z Lancet; 2012 Apr; 379(9825):1475-6. PubMed ID: 22530244 [No Abstract] [Full Text] [Related]
5. A new era of personalized medicine for cystic fibrosis - at last! Quon BS; Wilcox PG Can Respir J; 2015; 22(5):257-60. PubMed ID: 26083544 [TBL] [Abstract][Full Text] [Related]
6. A new era has dawned for persons with cystic fibrosis; however many knowledge gaps exist in our efforts to improve care. Hadjiliadis D; Clausen ES J Cyst Fibros; 2022 May; 21(3):383-384. PubMed ID: 35437232 [No Abstract] [Full Text] [Related]
7. Treatment of Fetal Cystic Fibrosis With Cystic Fibrosis Transmembrane Conductance Regulator Modulation Therapy. Blumenfeld YJ; Hintz SR; Aziz N; Barth RA; Spano JM; El-Sayed YY; Milla C Ann Intern Med; 2023 Jul; 176(7):1015-1016. PubMed ID: 37307583 [No Abstract] [Full Text] [Related]
8. Emerging technologies for cystic fibrosis transmembrane conductance regulator restoration in all people with CF. Egan ME Pediatr Pulmonol; 2021 Feb; 56 Suppl 1(Suppl 1):S32-S39. PubMed ID: 32681713 [TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics of cystic fibrosis treatment. Carter SC; McKone EF Pharmacogenomics; 2016 Aug; 17(13):1453-63. PubMed ID: 27490265 [TBL] [Abstract][Full Text] [Related]
12. Current progress in cystic fibrosis: is this a disease elusive to therapy? Brown C Pulm Pharmacol Ther; 2008 Aug; 21(4):585-7. PubMed ID: 18313958 [No Abstract] [Full Text] [Related]
13. [Challenges of personalized medicine for cystic fibrosis]. Corvol H; Taytard J; Tabary O; Le Rouzic P; Guillot L; Clement A Arch Pediatr; 2015 Jul; 22(7):778-86. PubMed ID: 26021452 [TBL] [Abstract][Full Text] [Related]
14. Making precision medicine personal for cystic fibrosis. Manfredi C; Tindall JM; Hong JS; Sorscher EJ Science; 2019 Jul; 365(6450):220-221. PubMed ID: 31320522 [No Abstract] [Full Text] [Related]
15. Type I, II, III, IV, and V cystic fibrosis transmembrane conductance regulator defects and opportunities for therapy. Choo-Kang LR; Zeitlin PL Curr Opin Pulm Med; 2000 Nov; 6(6):521-9. PubMed ID: 11100963 [TBL] [Abstract][Full Text] [Related]
18. Changing paradigms in the treatment of gastrointestinal complications of cystic fibrosis in the era of cystic fibrosis transmembrane conductance regulator modulators. Konrad J; Eber E; Stadlbauer V Paediatr Respir Rev; 2022 Jun; 42():9-16. PubMed ID: 33485777 [TBL] [Abstract][Full Text] [Related]